P-Cresol

P-Cresol

SCHEMBL1228560

Cc1ccc([O-])cc1.Cc1ccc([O-])cc1.Cc1ccc([O-])cc1.Cc1ccc([O-])cc1.[Zr+4]

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 7/20 0.57
TDP1 Q9NUW8 1/20 0.57
CA2 P00918 3/20 0.43
LPL P06858 1/20 0.43
LIPG Q9Y5X9 1/20 0.43
ORAI1 Q96D31 1/20 0.43
ORAI2 Q96SN7 1/20 0.43
ORAI3 Q9BRQ5 1/20 0.43
TRPV6 Q9H1D0 1/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CA1 P00915 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
HSD17B10 Q99714 1/20 0.39
CA12 O43570 1/20 0.39
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA5B Q9Y2D0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Cresol SCHEMBL8157029 0.93 ACHE (0.57) ACHETDP1CA2LPLLIPG
P-Cresol SCHEMBL6063969 0.93 ACHE (0.57) ACHETDP1CA2LPLLIPG
P-Cresol SCHEMBL1229546 0.93 ACHE (0.57) ACHETDP1CA2LPLLIPG
P-Cresol SCHEMBL10728842 0.93 ACHE (0.57) ACHETDP1CA2LPLLIPG
P-Cresol SCHEMBL585475 0.93
P-Cresol SCHEMBL1229426 0.93 ACHE (0.57) ACHETDP1CA2LPLLIPG
P-Cresol SCHEMBL585229 0.93
P-Cresol SCHEMBL8423863 0.93 ACHE (0.57) ACHETDP1CA2LPLLIPG
P-Cresol SCHEMBL585061 0.93
P-Cresol SCHEMBL6039896 0.90 ACHE (0.53) ACHETDP1CA2LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12623999-B2 Carbamate production method, carbamate ester production method, and urea derivative production method NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2026-05-12 US disclosed
US-20230212110-A1 CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHOD NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2023-07-06 US disclosed
EP-4169901-A1 CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHOD National Institute Of Advanced Industrial Science and Technology (JP) 2023-04-26 EP disclosed
EP-1746134-B1 CURABLE COMPOSITION WITH IMPROVED CURABILITY AND ADHESIVENESS KANEKA CORP (JP) 2019-09-04 EP disclosed
EP-1746135-B1 CURABLE COMPOSITION KANEKA CORP (JP) 2019-05-29 EP disclosed
US-7973108-B2 Curable composition KANEKA CORPORATION (JP) 2011-07-05 US disclosed
WO-2011072056-A2 CURE RATE CONTROL FOR ALKOXYSILYL-END-BLOCKED POLYMERS DOW CORNING COPORATION (US) 2011-06-16 WO disclosed
US-7910681-B2 Curable composition having improved adhesion KANEKA CORPORATION (JP) 2011-03-22 US disclosed
US-7893170-B2 Curable composition having improved curability and adhesion KANEKA CORPORATION (JP) 2011-02-22 US disclosed
US-20080319152-A1 Curable Composition KANEKA CORPORATION (JP) 2008-12-25 US disclosed
US-20080194773-A1 Polysiloxane from silanetriol group, a titanium, aluminum or a zirconium catalyst, and a low molecular weight compound containing a hydrolyzable silicon group; sealants, adhesives KANEKA CORPORATION (JP) 2008-08-14 US disclosed
US-20080076878-A1 Organic polymer having a silane tiol group, a titanium, aluminum or a zirconium catalyst, and a low molecular weight compound containing a hydrolyzable silicon group; sealants, adhesives KANEKA CORPORATION (JP) 2008-03-27 US disclosed
EP-1746135-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2007-01-24 EP disclosed
EP-1746134-A1 CURABLE COMPOSITION WITH IMPROVED CURABILITY AND ADHESIVENESS Kaneka Corporation (JP) 2007-01-24 EP disclosed
EP-1746133-A1 CURABLE COMPOSITION IMPROVED IN ADHESIVENESS Kaneka Corporation (JP) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12623999-B2 Carbamate production method, carbamate ester production method, and urea derivative production method CPS1, CA2, CHRM2 ACHE 1476/4885TDP1 2886/4885CA2 2/4885
US-20230212110-A1 CARBAMATE PRODUCTION METHOD, CARBAMATE ESTER PRODUCTION METHOD, AND UREA DERIVATIVE PRODUCTION METHOD CPS1, ATM, OAT ACHE 372/4885TDP1 732/4885CA2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.